marketshareAI

Avacta Group

AVCTHealthcare
30.50GBX
-1.61%
Market Cap
118.04M
Volume
1.38M
78% of avg
P/E Ratio
-0.03
EPS (TTM)
-9.46
Beta
-0.28
Day Range
30.00p - 33.00p
52 Week Range
26.00p30.50p86.40p
30.50p

Upcoming Events

July 2, 2025
Annual General Meeting
High Impact Event
Late Q4 2025
Expected release of initial data for FAP-Dox (AVA6000) in salivary gland cancer
High Impact Event
December 2025
IND submission for FAP-EXd (AVA6103)
High Impact Event
Early Q1 2026
Phase 1 trial of AVA6103 to begin
High Impact Event
Early Q1 2026
Cash runway expected to end
High Impact Event
Early Q2 2026
Planned start of Phase 2 trials for FAP-Dox in salivary gland cancer and triple negative breast cancer
High Impact Event
AVCT
NEUTRAL

Avacta Appoints New Chief Medical Officer and Business Development Advisor

The biotechnology company has appointed a new Chief Medical Officer and a business development advisor to strengthen its leadership team.

AVCT
NEUTRAL

Avacta Appoints Zeus Capital as Joint Broker

The healthcare company has appointed Zeus Capital as a joint broker, joining existing brokers Peel Hunt and Panmure Liberum.

AVCT
NEUTRAL

Avacta Reports New Response in FAP-Dox Phase 1b Trial

The life sciences company reports a new partial response in the dose expansion phase of its FAP-Dox Phase 1b trial for salivary gland cancer, a rare tumor type with high unmet need.

AVCT
NEUTRAL

Avacta Group Announces Posting of Annual Report and Revised Notice of AGM

The life sciences company provides details on the availability of its annual report and revised notice for the upcoming annual general meeting.

AVCT
BAD

Avacta Group Reports Widening Losses as It Transitions to Pure-Play Oncology Company

The biopharmaceutical company reported widening losses and a significant revenue decline as it transitions to a pure-play oncology focus. Despite clinical progress, financial pressures and development risks loom large.

AVCT
NEUTRAL

Avacta Delays Preliminary Results Announcement

The healthcare company has pushed back the release of its preliminary results for the year ended December 31, 2024.

AVCT
NEUTRAL

Avacta Appoints New Non-Executive Directors

The healthcare company has appointed two experienced industry executives to its board of directors.

AVCT
NEUTRAL

Avacta Delays Preliminary Results Announcement

The healthcare company has pushed back the release of its preliminary results for the year ended December 31, 2024 due to audit work delays.

AVCT
NEUTRAL

Avacta Group Announces Upcoming Results Presentation

The biotechnology company will announce its audited preliminary results for the year ended December 31, 2024 and host an investor presentation on May 29, 2025.

AVCT
NEUTRAL

Avacta Group Announces Investor Webinar

The life sciences company is hosting an investor webinar to discuss recent data presentations on its proprietary drug candidates.